## ADPT: Adaptive Biotechnologies Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.57 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (56% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($14.66)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Adaptive Biotechnologies announces subsidiary’s Series A financing round By Investing.com**
- Source: Investing.com Nigeria | 20251230T160907 | Bullish | Relevance: 100%
- Adaptive Biotechnologies announced that its 70%-owned subsidiary, Digital Biotechnologies, Inc., has commenced a Series A Preferred Stock financing round with anticipated proceeds of up to $15 million. Adaptive expects to maintain nearly 50% ownership and continue consolidating Digital Biotechnologies' financial results. This development follows strong Q3 2025 financial performance, strategic partnerships with Pfizer, and an "Overweight" rating from Piper Sandler despite increased market competition.

**2. Adaptive Biotechnologies Announces Series A Financing for Subsidiary**
- Source: TradingView — Track All Markets | 20251230T130907 | Somewhat-Bullish | Relevance: 100%
- Adaptive Biotechnologies announced a Series A financing round for its subsidiary, Digital Biotechnologies, with an initial closing achieved. The round is expected to generate up to $15 million in proceeds, and Adaptive Biotechnologies anticipates retaining nearly 50% ownership while consolidating Digital Biotechnologies' results into its own financials.

**3. Adaptive biotechnologies CPO Lo sells $76,895 in ADPT stock**
- Source: Investing.com | 20251229T000907 | Neutral | Relevance: 100%
- Francis Lo, Chief People Officer at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 4,394 shares of common stock for approximately $76,895 and exercised options to acquire the same number of shares. The company has shown significant growth with a 178.57% year-to-date return and strong revenue growth. Adaptive Biotechnologies also reported a strong Q3 2025 performance and announced non-exclusive agreements with Pfizer.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($1.31M) |
| Sells | 13 ($5.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Viking Global Invest: 19.7% (0.0%)
- Blackrock Inc.: 8.8% (-2.3%)
- Vanguard Group Inc: 7.4% (-0.0%)
- Ameriprise Financial: 3.9% (+84.3%)
- Sumitomo Mitsui Trus: 2.4% (-15.1%)

### Key Risks

1. High beta (2.20) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Insider selling cluster: $5.6M in recent transactions.
3. Elevated short interest (8.2%): bears positioning against stock.

### Catalysts

- Momentum building: MRS_20 improving +2.5% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.57 indicates undervaluation relative to growth. Balance sheet: strong liquidity (3.4x). Insider selling cluster ($5.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.5B |
| Beta | 2.20 |
| 52W Range | $5.96 - $20.76 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.57 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -2.0% to 0.5% (+2.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.5pp (needs >4.0% for momentum thesis). MRS_5 (-0.8%) diverging from MRS_20 - short-term weakness emerging. RSI neutral at 49. Volume at 56% of 20MA suggests lack of conviction. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.51% (CS: 56) | Neutral |
| RSI_14 | 49.3 | Neutral |
| MACD Histogram | 0.02 | Bullish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 0.991x | Below |
| vs SMA200 | 1.336x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $16.42
- **Stop Loss:** $14.66 (10.7% risk)
- **Target:** $19.94 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 750
- **Position Value:** $12,315.00
- **Portfolio %:** 12.32%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-10 (Est: $-0.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.14 | $0.06 | +143.3% |
| 2025Q2 | $-0.24 | $-0.17 | +28.6% |
| 2025Q1 | $-0.31 | $-0.20 | +35.5% |
| 2024Q4 | $-0.24 | $-0.23 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*